Iplex is no longer available in the United States.
Iplex (mecasermin rinfabate) is a combination of recombinant human insulin-like growth factor-1 (rh-IGF-1, mecasermin) and recombinant human insulin-like growth factor binding protein-3 (rh-IGFBP-3, rinfabate). It was originally intended for the long-term treatment of growth failure in children with severe deficiency of insulin-like growth factor (IGF-1) or with growth hormone (GH) gene deletion who have developed destructive antibodies to GH. Iplex is a man-made injectable version of IGF-1 that helps muscles and bones to grow.
The company no longer makes Iplex and is using any remaining supply as an orphan drug treatment for patients who have amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Iplex is being developed by another company as a treatment for a retina disorder in premature babies. Another company has developed a product called Increlex, containing mecasermin as the only active ingredient for treatment of growth failure in children with severe deficiency of insulin-like growth factor (IGF-1) or with growth hormone (GH) gene deletion who have developed destructive antibodies to GH.
Continue Learning about Pharmacology
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.